JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a small-molecule plasma kallikrein inhibitor, which could be the first oral on-demand therapy for hereditary angioedema and take “substantial” market share from currently approved injectables, the analyst tells investors in a research note. The firm sees approval as likely by the June 17 FDA action date.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV: